Combination of rituximab and tofacitinib IN THE TREATMENT of anti-MDA 5 antibody positive dermatomyositis – case reports

uvod.Anti-MDA5 dermatomiozitis (anti-MDA5 DM) jest rijetka sistemska autoimuna bolest udruena s MDA5 protutijelom (engl.anti-melanoma differentiation-associated gene 5 antibody) koju karakterizira amiopatija ili hipomiopatija s tipinim konim simptomima, u dijela bolesnika javlja se brzo progresivna intersticijska bolest plua (engl.rapid progressive interstital lung disease -RP-ILD), a posljednjih godina ee se povezuje s COVID-19 infekcijom i/ili vakcinacijom.Uglavnom je refraktoran na imunosupresivnu terapiju i ima lou prognozu

Publication Details

Journal
Reumatizam
Published
2024-10-28
DOI
https://doi.org/10.33004/reumatizam-supp-71-1-20
Primary Topic
Inflammatory Myopathies and Dermatomyositis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Combination of rituximab and tofacitinib IN THE TREATMENT of anti-MDA 5 antibody positive dermatomyositis – case reports

Reumatizam
Inflammatory Myopathies and Dermatomyositis
article

Combination of rituximab and tofacitinib IN THE TREATMENT of anti-MDA 5 antibody positive dermatomyositis – case reports

article en

Abstract

uvod.Anti-MDA5 dermatomiozitis (anti-MDA5 DM) jest rijetka sistemska autoimuna bolest udruena s MDA5 protutijelom (engl.anti-melanoma differentiation-associated gene 5 antibody) koju karakterizira amiopatija ili hipomiopatija s tipinim konim simptomima, u dijela bolesnika javlja se brzo progresivna intersticijska bolest plua (engl.rapid progressive interstital lung disease -RP-ILD), a posljednjih godina ee se povezuje s COVID-19 infekcijom i/ili vakcinacijom.Uglavnom je refraktoran na imunosupresivnu terapiju i ima lou prognozu

ReumatizamVol. 71(Supp1)
Openalex Percentile: Top 63%
Inflammatory Myopathies and Dermatomyositis
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Combination of rituximab and tofacitinib IN THE TREATMENT of anti-MDA 5 antibody positive dermatomyositis – case reports · Reumatizam (2024) | TGRS Research Map | TGRS